All Stories

  1. Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery –Who Is Referring Them?
  2. Effects of Hypopituitarism Due to Sheehan's Syndrome on Bone Mineral Density: A Multicentric Study in Asian Indians
  3. New directions in MEN1 management: navigating the new clinical practice guidelines
  4. Bone Density, Microarchitecture, and Geometry Assessment in Patients with Pachydermoperiostosis Using Second-Generation High-Resolution Peripheral Quantitative Computed Tomography: A Case–Control Study
  5. A Novel De Novo Nonsense Pathogenic Variant in IGSF1 Resulting in Central Hypothyroidism and Transient GH Deficiency
  6. RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly
  7. Clinical features of acromegaly
  8. Bone mineral density, turnover, and microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography in patients with Sheehan’s syndrome
  9. Tall stature and gigantism in adult patients with acromegaly
  10. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases
  11. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations
  12. Multiple Endocrine Neoplasia and Familial Isolated Pituitary Adenoma in the Paediatric Population
  13. Genetic Testing in Hereditary Pituitary Tumors
  14. Pharmacological and Genetic Disruption of C-Type Natriuretic Peptide (nppcl) Expression in Zebrafish (Danio rerio) Causes Stunted Growth during Development
  15. Live Fast, Die Young?
  16. Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism
  17. Tumour microenvironment and pituitary tumour behaviour
  18. Insulinomatosis: new aspects
  19. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review
  20. Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours
  21. AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene
  22. Ockham’s Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle
  23. Glucose and lipid metabolism abnormalities in Cushing’s syndrome
  24. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients
  25. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
  26. Approach to the Patient With Pseudoacromegaly
  27. Sex-biased islet β cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males
  28. Serum Inflammation-based Scores in Endocrine Tumors
  29. Genetics of Acromegaly and Gigantism
  30. Molecular characterization of DICER1-mutated pituitary blastoma
  31. The clinical aspects of pituitary tumour genetics
  32. Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research
  33. Pre-operative serum inflammation-based scores in patients with pituitary adenomas
  34. Update on the Genetics of Pituitary Tumors
  35. The tumour microenvironment of pituitary neuroendocrine tumours
  36. Unusual Combination of MEN-1 and the Contiguous Gene Deletion Syndrome of CAH and Ehlers-Danlos Syndrome (CAH-X)
  37. XAF1 as a modifier of p53 function and cancer susceptibility
  38. Phenotypic and genotypic features of a large kindred with a germline AIP variant
  39. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial
  40. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms
  41. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors
  42. Pachydermoperiostosis mimicking the acral abnormalities of acromegaly
  43. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
  44. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness
  45. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
  46. Redefining the perioperative stress response: a narrative review
  47. Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency
  48. Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature
  49. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
  50. Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules
  51. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation
  52. Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion
  53. Phosphodiesterases and cAMP Pathway in Pituitary Diseases
  54. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors
  55. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
  56. Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects
  57. The current landscape of European registries for rare endocrine conditions
  58. Assessment of Cardiavascular Changes following Trans-sphenoidal Surgery in Acromegalic Patients
  59. Genetics of Pituitary Tumours
  60. Proteomic Analysis of the Human Anterior Pituitary Gland
  61. Pseudoacromegaly
  62. Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas
  63. Pituitary Pathology and Gene Expression in Acromegalic Cats
  64. Coexisting pituitary and non-pituitary gigantism in the same family
  65. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
  66. Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome
  67. Clinical and Pathological Aspects of Silent Pituitary Adenomas
  68. Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas
  69. Macimorelin as a Diagnostic Test for Adult GH Deficiency
  70. A novel DICER1 mutation in familial multinodular goitre
  71. UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS
  72. Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2
  73. In vivo bioassay to test the pathogenicity of missense human AIP variants
  74. De novo HNF1 homeobox B mutation as a cause for chronic, treatment-resistant hypomagnesaemia
  75. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target
  76. Risk category system to identify pituitary adenoma patients with AIP mutations
  77. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus
  78. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
  79. Cantú syndrome with coexisting familial pituitary adenoma
  80. Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland
  81. Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members’ View in anAIPMutation-Positive Family
  82. Metabolic Syndrome in Cushing's Syndrome Patients
  83. Preliminaries
  84. AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation
  85. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor
  86. AIP and the somatostatin system in pituitary tumours
  87. Mechanical, hormonal and metabolic influences on blood vessels, blood flow and bone
  88. Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion
  89. Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution
  90. In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism
  91. PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex
  92. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma
  93. A unique haplotype of RCCX copy number variation: from the clinics of congenital adrenal hyperplasia to evolutionary genetics
  94. Pituitary Carcinoma in a Patient with an SDHB Mutation
  95. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
  96. Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening
  97. Genetic Aspects of Pituitary Adenomas
  98. Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients
  99. Social, educational and vocational outcomes in patients with childhood-onset and young-adult-onset growth hormone deficiency
  100. The genetic background of acromegaly
  101. Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas
  102. Pachydermoperiostosis Masquerading as Acromegaly
  103. Metformin prevents metabolic side effects during systemic glucocorticoid treatment
  104. Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour
  105. Echocardiographic improvements following transsphenoidal surgery for acromegaly
  106. Genetics of pituitary adenomas
  107. Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas
  108. Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers
  109. The clinical, pathological and molecular differences between sparsely and densely granulated somatotroph adenomas
  110. Glioma in an AIP mutation carrier patient
  111. Pseudoacromegaly - a differential diagnostic problem for acromegaly
  112. Olfactory neuroblastoma: a multi centre clinical and pathological review
  113. Metformin alters an anti-proliferative effect of Mitotane in a human adrenocortical cancer (H295R) cell line: preliminary results
  114. The role of the microenvironment in the invasive phenotype of familial pituitary tumours
  115. Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma
  116. ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma
  117. Novel Genetic Causes of Pituitary Adenomas
  118. Increased Population Risk ofAIP-Related Acromegaly and Gigantism in Ireland
  119. Gigantism: X-linked acrogigantism and GPR101 mutations
  120. Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance
  121. Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With MissenseAIPMutations
  122. Signaling network map of the aryl hydrocarbon receptor
  123. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study
  124. AIP inactivation leads to pituitary enlargement in the Zebrafish embryo model
  125. The Drosophila AIP orthologue is essential for actin cytoskeleton stabilisation and cell adhesion
  126. cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors
  127. SomaticGPR101Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management
  128. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction
  129. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience
  130. Clinicopathologic features of familial pituitary adenomas
  131. Cancerous leptomeningitis and familial congenital hypopituitarism
  132. AIP and the somatostatin signalling in pituitary tumours
  133. Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?
  134. Endocrine Tumor Genetics: Challenging Issues
  135. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
  136. Diagnosis of Acromegaly
  137. Clinical Features of Acromegaly☆
  138. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
  139. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways
  140. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
  141. Childhood somatotroph pituitary adenomas due to aryl hydrocarbon receptor interacting protein (AIP) gene mutations
  142. Pegvisomant treatment for X-linked acrogigantism syndrome
  143. Achieving a consensus on managing idiopathic thickening of the pituitary stalk through a national multidisciplinary forum, meeting virtually
  144. In vitroeffects of Imatinib on somatotrophinoma cell line
  145. Silencing of aryl hydrocarbon receptor protein (AIP) up-regulates the small Rho GTPase, CDC42
  146. Novel targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma
  147. Potential molecular mechanism of AIP-mediated cellular invasion
  148. The effect of AIP on AHR transcriptional activity: implications forAIPmutations pathogenicity
  149. Investigation of the invasive phenotype of AIP-mutated pituitary adenomas
  150. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study
  151. Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma
  152. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis inAIPMutation Carriers
  153. The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress
  154. Prostatic hyperplasia in acromegaly
  155. Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1
  156. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease
  157. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas
  158. Metabolic comorbidities in Cushing's syndrome
  159. Ghrelin
  160. Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter
  161. The ubiquitin-specific protease 8 gene is frequently mutated in adenomas causing Cushing's disease
  162. Pituitary apoplexy in GH-deficient adults treated with GH - a KIMS database retrospective study
  163. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
  164. Excessive Growth Hormone Expression in Male GH Transgenic Mice Adversely Alters Bone Architecture and Mechanical Strength
  165. Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia
  166. Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort
  167. Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas
  168. Evaluation of genotype–phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome
  169. Prostatic hyperplasia in acromegaly, a myth or reality: a case–control study
  170. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database
  171. An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene
  172. Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma
  173. A 25-Year-Old Woman with Headache and Joint Pain
  174. Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team
  175. The role of ghrelin in weight-regulation disorders: Implications in clinical practice
  176. Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas
  177. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort
  178. Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis
  179. Paediatric pituitary adenomas: rare, complex, and by no means benign
  180. Common Genetic Variants of the Human Steroid 21-Hydroxylase Gene (CYP21A2) Are Related to Differences in Circulating Hormone Levels
  181. Combination of 13-CisRetinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice
  182. Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis
  183. 122 Cardiac Abnormalities are Common in Patients Diagnosed with Phaeochromocytoma as Detected by Cardiovascular Magnetic Resonance Imaging
  184. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations
  185. Human AIP gene rescue lethality in a Drosophila melanogaster knockout model of AIP orthologue
  186. The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells
  187. Clinical Experience in the Screening and Management of a Large Kindred With Familial Isolated Pituitary Adenoma Due to an Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutation
  188. Analysis of the AIP gene promoter
  189. Kallmann syndrome, gender dysphoria, thrombophilia and multiple sclerosis: a complex case report
  190. High incidence of cardiac involvement in patients diagnosed with phaeochromocytoma: a clinical study using cardiovascular magnetic resonance imaging
  191. RET mutation negative familial medullary thyroid carcinoma: four families and literature review
  192. Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation
  193. Epidemiology and etiopathogenesis of pituitary adenomas
  194. Metformin—mode of action and clinical implications for diabetes and cancer
  195. Preface
  196. Familial pituitary tumors
  197. Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?
  198. MicroRNAs: Suggested role in pituitary adenoma pathogenesis
  199. Effects of smoking cessation on  -cell function, insulin sensitivity, body weight, and appetite
  200. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release
  201. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus
  202. A Comprehensive Next Generation Sequencing–Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma
  203. Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery
  204. Novel pathway for somatostatin analogs in patients with acromegaly
  205. GH excess in bGH transgenic mice adversely affects bone density, architecture and quality
  206. AIP (aryl hydrocarbon receptor interacting protein)
  207. Gene expression profiling of familial and sporadic pituitary adenomas
  208. Genetic and clinical characteristics of Serbian FIPA families
  209. Drosophila melanogasteras a model organism to study aryl hydrocarbon receptor interacting protein gene function
  210. A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype
  211. Familial Pituitary Adenomas
  212. Genes and giants
  213. De Novo HNF1b mutation as a cause for chronic treatment-resistant hypomagnesaemia
  214. Excessive GH expression in bGH transgenic mice adversely alters bone architecture and quality
  215. The role of microRNA miR-34a in the regulation of aryl hydrocarbon receptor interacting protein
  216. Invasion signature' revealed by the analysis of AIP positive and AIP mutation negative human pituitary adenomas
  217. Creation of a locus-specific database for AIP mutations
  218. Genetics of the Ghrelin System
  219. Genetics of Pituitary Adenomas
  220. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism
  221. Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition
  222. Familial isolated pituitary adenomas: An emerging clinical entity
  223. ACTH-secreting Crooke cell carcinoma of the pituitary
  224. Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma
  225. 2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size
  226. Familial pituitary adenomas – who should be tested for AIP mutations?
  227. Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
  228. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro
  229. Oncogene-induced senescence in pituitary adenomas and carcinomas
  230. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines
  231. Mice lacking AMP-activated protein kinase  1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment
  232. Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide
  233. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
  234. Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor
  235. Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker
  236. Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues
  237. Measurement of AMP-Activated Protein Kinase Activity and Expression in Response to Ghrelin
  238. Cardiovascular changes in patients with adult-onset growth hormone deficiency assessed by CMR
  239. Cardiovascular changes in patients with acromegaly assessed by CMR
  240. Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes
  241. The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor α
  242. Ghrelin in obesity and endocrine diseases
  243. miR-107 Is Overexpressed in Pituitary Adenomas and Inhibits the Expression of Aryl Hydrocarbon Receptor-Interacting Protein (AIP)
  244. Familial isolated pituitary adenoma syndrome
  245. Specific electrocardiographic features associated with Cushing’s disease
  246. AIP and its interacting partners
  247. WITHDRAWN: Ghrelin in obesity and endocrine diseases
  248. The ghrelin/GOAT/GHS-R system and energy metabolism
  249. AIPMutation in Pituitary Adenomas in the 18th Century and Today
  250. 2.3.11 Acromegaly
  251. The expression of ghrelin O-acyltransferase (GOAT) in human tissues
  252. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes
  253. MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas
  254. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening
  255. Down-Regulation of Wee1 Kinase by a Specific Subset of microRNA in Human Sporadic Pituitary Adenomas
  256. AIP gene and familial isolated pituitary adenomas
  257. Cyclins and their related proteins in pituitary tumourigenesis
  258. Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma
  259. Down-Regulation of Wee1 Kinase by a Specific Subset of microRNAs in Human Sporadic Pituitary Adenomas
  260. Alterations in Adipose Tissue during Critical Illness
  261. Treatment of acromegaly
  262. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass
  263. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)
  264. AMP-activated protein kinase (AMPK) regulates in vitro bone formation and bone mass in vivo
  265. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas
  266. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families
  267. Ghrelin’s Role as a Major Regulator of Appetite and Its Other Functions in Neuroendocrinology
  268. Molecular Genetics of the Aip Gene in Familial Pituitary Tumorigenesis
  269. PL10 The curious case of ghrelin
  270. Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues
  271. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
  272. AMPK as a mediator of hormonal signalling
  273. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
  274. The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes
  275. Recent Clinical and Pathophysiological Advances in Non-Functioning Pituitary Adenomas
  276. Association Studies onGhrelinandGhrelin ReceptorGene Polymorphisms With Obesity
  277. Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation
  278. AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation
  279. Assessment of p27 (cyclin‐dependent kinase inhibitor 1B) and aryl hydrocarbon receptor‐interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations
  280. Familial Isolated Pituitary Adenomas
  281. Familial Isolated Pituitary Adenomas
  282. A Genetic Study of the Ghrelin and Growth Hormone Secretagogue Receptor (GHSR) Genes and Stature
  283. STOP AKTING TO TREAT ENDOCRINE TUMOURS
  284. The Yin and Yang of the Ghrelin Gene Products
  285. The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors
  286. Changes in Adenosine 5′-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing’s Syndrome
  287. Ghrelin Receptor Gene Polymorphisms and Body Size in Children and Adults
  288. Protein western array analysis in human pituitary tumours: insights and limitations
  289. The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas
  290. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome
  291. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
  292. The role of somatostatin analogues in the treatment of neuroendocrine tumours
  293. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients
  294. The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System
  295. The Role of AMP-Activated Protein Kinase in Obesity
  296. Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line
  297. Contents / Foreword / Preface
  298. A new variation in the promoter region, the −604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance
  299. Metabolic and hormonal changes during the refeeding period of prolonged fasting
  300. Examining the Candidacy of Ghrelin as a Gene Responsible for Variation in Adult Stature in a United Kingdom Population with Type 2 Diabetes
  301. Ghrelin in neuroendocrine organs and tumours
  302. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas
  303. Ghrelin, the peripheral hunger hormone
  304. Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase
  305. The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression
  306. PPAR-? expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-? receptor
  307. Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man
  308. Effect of Gastric Bypass and Gastric Banding on Proneurotensin Levels in Morbidly Obese Patients
  309. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours
  310. Expanding role of AMPK in endocrinology
  311. Ghrelin and cardiovascular health
  312. Refeeding David Blaine — Studies after a 44-Day Fast
  313. Differential gene expression in pituitary adenomas by oligonucleotide array analysis
  314. Enhanced protein kinase B/Akt signalling in pituitary tumours
  315. Fasting and Postprandial Hyperghrelinemia in Prader-Willi Syndrome Is Partially Explained by Hypoinsulinemia, and Is Not Due to Peptide YY3–36Deficiency or Seen in Hypothalamic Obesity Due to Craniopharyngioma
  316. Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase
  317. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
  318. Striant™ SR: a novel, effective and convenient testosterone therapy for male hypogonadism
  319. Akting and Cycling: A Tale of the Pituitary
  320. Theobromine inhibits sensory nerve activation and cough
  321. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
  322. Ghrelin: update on a novel hormonal system
  323. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway
  324. A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males
  325. Ghrelin?a hormone with multiple functions
  326. Elevated Fasting Plasma Ghrelin in Prader-Willi Syndrome Adults Is Not Solely Explained by Their Reduced Visceral Adiposity and Insulin Resistance
  327. Non-Growth Hormone Endocrine Actions of Ghrelin
  328. Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas
  329. The Kruppel-like transcription factor 6 gene in sporadic pituitary tumours
  330. Reduced expression of the growth hormone and type 1 insulin‐like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor
  331. Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro
  332. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours
  333. Ghrelin is Released from Rat Hypothalamic Explants and Stimulates Corticotrophin-releasing Hormone and Arginine-vasopressin
  334. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency
  335. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei
  336. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours
  337. A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children
  338. A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children
  339. Cell Cycle Dysregulation in Human Pituitary Tumours
  340. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans
  341. Expression of Phosphorylated p27Kip1Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors
  342. Expression of Phosphorylated p27Kip1 Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors
  343. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans
  344. Optimal Response Criteria for the Human CRH Test in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome
  345. Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease
  346. The Effect of Growth Hormone Secretagogues and Neuropeptide Y on Hypothalamic Hormone Release from Acute Rat Hypothalamic Explants
  347. The release of leptin and its effect on hormone release from human pituitary adenomas
  348. Expression of 11β-Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors
  349. Ghrelin, the endogenous ligand to the growth hormone secretagogue receptor — expression in human hypothalamus and pituitary
  350. Expression of 11 -Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors
  351. Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly
  352. The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors1
  353. Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors
  354. The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors
  355. Presence of Ghrelin in Normal and Adenomatous Human Pituitary
  356. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
  357. Expression of the Pituitary Transcription Factor Ptx-1, But Not That of theTrans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreasedα -Subunit Secretion1
  358. Expression of the Pituitary Transcription Factor Ptx-1, But Not That of the Trans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreased  -Subunit Secretion
  359. Low Expression of the Cell Cycle Inhibitor p27Kip1in Normal Corticotroph Cells, Corticotroph Tumors, and Malignant Pituitary Tumors
  360. Hexarelin as a test of pituitary reserve in patients with pituitary disease
  361. The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin
  362. The growth hormone secretagogue receptor
  363. Expression of menin gene mRNA in pituitary tumours
  364. The Effects of GH-Secretagogues on Human Pituitary Cells in Culture and on Rat Hypothalamic Tissue
  365. Leptin and the thyroid — A puzzle with missing pieces
  366. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors1
  367. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors
  368. The Pathophysiology of Circulating Corticotropin-Releasing Hormone-Binding Protein Levels in the Human
  369. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity
  370. Differential stimulation of corticol and dehydropiandrosterone levels by food in obese and normal subjects: relation to body fat distribution
  371. Intérêt clinique des neuropeptides GHRH et GHRP
  372. Diagnosis of Growth Hormone Deficiency in Adults
  373. The effect of an opiate antagonist on the hormonal changes induced by hexarelin
  374. Growth hormone-releasing peptide and its analogues
  375. Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method